ClinicalTrials.gg
Active, not recruitingNCT03022188Updated Feb 21, 2024

Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma

An observational study in Neuroendocrine Tumors, sponsored by Société Française d'Endoscopie Digestive. Active, not recruiting at 22 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-21.

Sponsored by Société Française d'Endoscopie Digestive · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Neuroendocrine Tumors with a site in France — 19 open to participants now, 25 under way, 8 of them phase 3. Neuroendocrine Tumors · France.

Planned enrollment
12th of 20
100 · median 118
Started
2017
with 4 others
Observational
20 of 60
6 open now
Primary completion
2022-07
later than 0 of 24 live
Registered
21st of 60
by date

Among the 60 studies in Neuroendocrine Tumors with a site in France, this one is the 12th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2017, is one of 20 observational ones, reaches primary completion later than 0 of the 24 other live ones, and was the 21st registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

19 of the 60 studies in Neuroendocrine Tumors with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Neuroendocrine Tumors with a site in France, or all of them as a file.
02

Study summary

Neuroendocrine tumors (NETs) and carcinomas account for 10-15 % of all pancreatic incidentalomas. The management of pancreatic NETs depends on tumor stage and on presence or not of hormonal syndrome. The therapeutic approach for hormonally functional tumor, or large tumor (> 2 cm) with local, vascular or lymph nodes invasion, highly suggestive of malignancy, or in presence of metastasis, is well admitted: surgery is indicated or should be discussed. However, the attitude is less consensual for small (≤ 2 cm) non-functioning (NF) and non-metastatic lesions. In English, American or French recommendations, systematic surgical resection with lymphadenectomy is currently recommended in all medically fit patients. The follow-up (FU) is possible for tumors \<2 cm (T1) located in the pancreatic head and for which enucleation is not feasible. Several recently published retrospective studies discuss the "non- surgical" management of the small NF incidentally detected pancreatic NETs (IPNETs) and highlight the necessity of developing guidelines for management of these patients. A strict correlation between tumor size and malignancy of these tumors was demonstrated in the single-center retrospective Italian study of Bettini and col., which included all patients with NF PNETs who underwent curative (R0) resection during 18 years. In the group of 51 patients with small size of T (2 cm or less), incidentally discovered, the majority of lesion was benign, and the authors concluded that follow-up can be proposed in patients with incidentally discovered NF PNETs ≤ 2 cm. However in despite of small size and asymptomatic character of the tumor, the rate of malignancy of NF IPNETs ≤ 2 cm was estimated to be 24 % (in 18% and 6% of cases, uncertain behaviour and carcinoma were present). Given the inherent morbidities associated with pancreatic surgery, a risk-benefit calculation may favour surveillance rather than surgery in highly selected patients. Thus, a better understanding of NF IPNETs and identification of their prognostic factors can be of help to select a subgroup of patients who could benefit from a long-term surveillance rather than a systematic surgical resection. Clearly, large prospective trials are needed to validate this approach.

Read the detailed description

With increasing use of high-resolution conventional imaging, pancreatic incidentalomas are being diagnosed more frequently. In two recent surgical series, neuroendocrine tumors (NETs) and carcinomas account for 10-15 % of all pancreatic incidentalomas, the majority ( 75-90 % of cases) well differentiated. The factors affecting the behaviour of pancreatic NETs are differentiation, histological grade, staging, size and intratumoral microvascular density. In updated World Health Organization (WHO) classification, the grading system is based on tumor differentiation, the rate of proliferation and Ki-67 index. The management of pancreatic NETs depends on tumor stage and on presence or not of hormonal syndrome. By definition, the incidentally discovered pancreatic NETs (PNETs) are unassociated with hormonal syndromes (nonfunctioning) and detected in patients who undergo diagnostic evaluations for unrelated conditions.

The therapeutic approach for hormonally functional tumor, or large tumor (> 2 cm) with local, vascular or lymph nodes invasion, highly suggestive of malignancy, or in presence of metastasis, is well admitted: surgery is indicated or should be discussed.

However, the attitude is less consensual for small (≤ 2 cm) non-functioning (NF) and non-metastatic lesions. There is a paucity of literature reporting pancreatic neuroendocrine incidentalomas and their characteristics. However, given their increased incidence, they are an emerging problem and require changes in treatment guidelines. In English, American or French recommendations, systematic surgical resection with lymphadenectomy is currently recommended in all medically fit patients. The follow-up (FU) is possible for tumors \<2 cm (T1) located in the pancreatic head and for which enucleation is not feasible. This therapeutic approach has two limitations: 1) the significant incidence of these tumors, because of the widespread use of routine imaging, and the improved technology of multi detector CT scan, the fortuitous discovery of small pancreatic incidentalomas is becoming more common. 2) Pancreatic surgery carries significant postoperative morbidity even in high-volume tertiary centers and even in parenchyma-preserving resection. This may results in many pancreatic resections for tumors with unknown natural history. On the other hand, the follow-up may be a factor of considerable anxiety, and carries the risk, actually difficult to assess, to let the tumor grow between two monitoring controls, with the possible evolution to the irreversible metastatic stage of the disease.

As a result, the investigators are unceasingly facing a dilemma: how to manage asymptomatic patients with small incidentally detected, potentially benign NETs? Several recently published retrospective studies discuss the "non- surgical" management of the small NF incidentally detected pancreatic NETs (IPNETs) and highlight the necessity of developing guidelines for management of these patients. A strict correlation between tumor size and malignancy of these tumors was demonstrated in the single-center retrospective Italian study of Bettini and col. , which included all patients with NF PNETs who underwent curative (R0) resection during 18 years. In the group of 51 patients with small size of T (2 cm or less), incidentally discovered, the majority of lesion was benign, and the authors concluded that follow-up can be proposed in patients with incidentally discovered NF PNETs ≤ 2 cm. However in despite of small size and asymptomatic character of the tumor, the rate of malignancy of NF IPNETs ≤ 2 cm was estimated to be 24 % (in 18% and 6% of cases, uncertain behaviour and carcinoma were present).

Given the inherent morbidities associated with pancreatic surgery, a risk-benefit calculation may favour surveillance rather than surgery in highly selected patients. Thus, a better understanding of NF IPNETs and identification of their prognostic factors can be of help to select a subgroup of patients who could benefit from a long-term surveillance rather than a systematic surgical resection. Clearly, large prospective trials are needed to validate this approach.

03

Conditions studied

  • Neuroendocrine Tumors

Keywords

  • pancreatic incidentaloma
  • pancreatic neuroendocrine tumor
  • EUS-guided fine-needle aspiration
  • contrast-enhanced endoscopic ultrasound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with pancreatic tumors \<2cm (stage 1 discovered incidentally.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients older than 18 years old
  • with a small size ≤ 2 cm (stage I) non-functioning pancreatic neuroendocrine incidentaloma, cytologically and/or histologically proved or, in case of impossibility to obtain a cyto-histological specimen, with highly suggested diagnosis by imaging (early, homogenous enhancement at computerized tomography (CT- scan) and/or magnetic resonance Imaging (MR)I and positivity at somatostatin receptor scintigraphy (SRS))
  • patient ASA 1-2 (assessed according to classification system of American Society of Anesthesiology)
  • after geriatric evaluation for the patients older than 75 y.o
  • affiliated to a social security system
  • with signed consent for study enrolment.

Exclusion criteria

Exclusion Criteria:

  • Patients \< 18 years old
  • Patients with NET with size > 2 cm ( stage II-IV) or NEC and/or with presence of signs suspicious of
  • Patients with a functioning NET or NEC (clinical syndrome caused by excess hormonal secretion, as insulinoma or Zollinger -Ellison syndrome)
  • Patients with multiple pancreatic neuroendocrine tumors
  • Patients with multiple endocrine neoplasia type 1 (MEN1)
  • Patients with suspicion of non- neuroendocrine tumor
  • Patient ASA 3-4 (assessed according to classification system of American Society of Anesthesiology)
  • Patients with other malignant disease under treatment or with under 5 years remission, except in situ or intramucosal carcinoma.
  • Pregnant or breastfeeding women
  • Patients judged not able to perform the monitoring
  • Absence of signed consent for study enrolment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observational

    Observational

06

What researchers measure

Primary outcomes

  1. rate of malignancy among nonfunctioning (NF) small (≤ 2 cm) pancreatic neuroendocrine incidentalomas (PNEI).

    * any G3 tumor \* * G2 \* or G1 \* tumor with lymph node metastases and / or distant metastasis * G2 or G1 tumor with recurrence during the clinical and morphological surveillance after surgical treatment

    Time frame: 36 months

Secondary outcomes

  1. progression rate among NF-PNEI ≤ 2cm in case of non-surgical management

    - significant increase of tumor size within one year \> 20% on radiological examination or \> 2 mm at endoscopic ultrasound ; - appearance of metastatic lymph nodes and / or distant metastases

    Time frame: 36 months

  2. determination of Ki67 value

    determination of Ki67 value on cytological samples obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and on surgical specimen

    Time frame: 36 months

  3. performance of contrast harmonic endoscopic ultrasound (CH-EUS) for the diagnosis of malignancy

    assessment of sensibility (Se), specificity (Spe), positive predictive value (PPV), negative predctive value (NPV) and accuracy of CH-EUS for the diagnosis of malignancy, appreciated by tumor microvascularisation assessment during CH-EUS procédures and correlation with tumor microvascular density appreciated on surgical specimen

    Time frame: 36 months

  4. rate of surgical treatment, delay from diagnosis to surgery and rationale

    number of patients having undergone surgical treatment / total number of patients included in the study ; - number of days between diagnosis and surgical treatment ,

    Time frame: 36 months

  5. the rate of non-surgical management and the reasons that determined the choice of this therapeutic option

    - number of patients with non- surgical management (monitoring) / total number of patients included in the study

    Time frame: 36 months

  6. to assess the morbidity among the patients with surgical treatment

    -Morbidity defined as all complication occurring after surgical resection until discharge and/or readmission, and will be grade according to the Clavien-Dindo classification. Postoperative pancreatic fistula, haemorrhage, and delayed gastric emptying were defined according to the International Study Group of Pancreatic Surgery

    Time frame: 36 months

  7. to assess the mortality among the patients with surgical treatment

    Perioperative mortality is death in relation to surgery, defined as death after surgical resection until discharge and/or readmission

    Time frame: 36 monts

  8. to assess the overall survival (OS) among the patients with surgical treatment

    OS defined as the time from diagnosis to death of any cause

    Time frame: 36 months

  9. disease specific survival (DSS) among the patients with surgical treatment

    DSS defined as the time from diagnosis to disease-related death and censored at the last follow-up date if no events had occurred.

    Time frame: 36 months

  10. to assess the progression-free survival (PFS) among the patients with surgical treatment

    PFS is the period during and after treatment in which a participant is living with a disease that does not get worse defined and is defined as the time from diagnosis until 1) loco-regional or systemic recurrence, 2) second malignancy, or 3) death from any cause; late deaths not related to cancer or its treatment are excluded

    Time frame: 36 months

  11. to assess the morbidity among the patients with non-surgical treatment

    morbidity defined as all complication occurred after endoscopic ultrasound procedures until discharge and/or readmission

    Time frame: 36 months

  12. to assess the mortality among the patients with non-surgical treatment

    mortality defined as death in relation to endoscopic ultrasound procedure, occured until discharge and/or readmission

    Time frame: 36 months

  13. to assess the overal survival (OS) among the patients with non-surgical treatment

    OS defined as the time from diagnosis to death of any cause

    Time frame: 36 months

  14. to assess the disease free survival (DSS) among the patients with non-surgical treatment

    DSS defined as the time from diagnosis to disease-related death and censored at the last follow-up date if no events had occurred.

    Time frame: 36 months

  15. to assess the progression-free survival (PFS) among the patients with non-surgical treatment

    PFS is the period during and after treatment in which a participant is living with a disease that does not get worse defined and is defined as the time from diagnosis until 1) loco-regional or systemic recurrence, 2) second malignancy, or 3) death from any cause; late deaths not related to cancer or its treatment are excluded

    Time frame: 36 months

  16. Quality of life assessment at baseline, 12, 24 and 36 months

    The quality of life will be assessed using the 12-item Short-Form Health Survey (SF12) self- questionnaire

    Time frame: baseline, 12, 24 and 36 months

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jul 2022, 66 months.

Of 54 observational studies under Neuroendocrine Tumors, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 239. This study's 66 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2017
First posted
Jan 16, 2017
StartActual
Jan 10, 2017
Primary completionActual
Jul 2022
CompletionEst.
Dec 2026
Last update
Feb 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03022188
Lead sponsor
Société Française d'Endoscopie Digestive
Responsible party
Gincul Rodica (Medical Doctor, Principal Investigator, Société Française d'Endoscopie Digestive) — Principal investigator
First posted
Jan 16, 2017
Start date
Jan 10, 2017
Primary completion
Jul 2022
Completion
Dec 2026 (estimated)
Last update
Feb 21, 2024

Study contacts

Rodica Gincul, MD
principal investigator · Société Française d'Endoscopie Digestive

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion